JP7288154B2 - 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物 - Google Patents

重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物 Download PDF

Info

Publication number
JP7288154B2
JP7288154B2 JP2022574099A JP2022574099A JP7288154B2 JP 7288154 B2 JP7288154 B2 JP 7288154B2 JP 2022574099 A JP2022574099 A JP 2022574099A JP 2022574099 A JP2022574099 A JP 2022574099A JP 7288154 B2 JP7288154 B2 JP 7288154B2
Authority
JP
Japan
Prior art keywords
compound
dimethyltryptamine
compounds
formula
deuterated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022574099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520256A (ja
Inventor
ランズ，ピーター
ベンウェイ，ティファニー
ジョエル，ゼラ
レイゼル，マリー
ジェイムズ，エレン
Original Assignee
スモール ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2008303.6A external-priority patent/GB2585978B/en
Priority claimed from GBGB2018950.2A external-priority patent/GB202018950D0/en
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from US17/108,679 external-priority patent/US20220168274A1/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Application filed by スモール ファーマ リミテッド filed Critical スモール ファーマ リミテッド
Priority claimed from PCT/EP2021/060750 external-priority patent/WO2021116503A2/en
Publication of JP2023520256A publication Critical patent/JP2023520256A/ja
Publication of JP7288154B2 publication Critical patent/JP7288154B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
JP2022574099A 2020-06-02 2021-04-23 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物 Active JP7288154B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
GB2008303.6 2020-06-02
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
EPPCT/EP2020/065244 2020-06-02
US16/890,664 US11771681B2 (en) 2019-06-03 2020-06-02 Therapeutic compounds
US16/890,664 2020-06-02
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,679 US20220168274A1 (en) 2020-12-01 2020-12-01 Parenteral Formulation
US17/108,938 2020-12-01
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,679 2020-12-01
GB2018955.1 2020-12-01
GB2018950.2 2020-12-01
US17/208,583 2021-03-22
GB2103981.3 2021-03-22
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
PCT/EP2021/060750 WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds

Publications (2)

Publication Number Publication Date
JP2023520256A JP2023520256A (ja) 2023-05-16
JP7288154B2 true JP7288154B2 (ja) 2023-06-06

Family

ID=84083617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574099A Active JP7288154B2 (ja) 2020-06-02 2021-04-23 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物

Country Status (10)

Country Link
JP (1) JP7288154B2 (pl)
KR (1) KR102589605B1 (pl)
CN (1) CN116056763B (pl)
AU (1) AU2021204158B2 (pl)
CA (1) CA3179161C (pl)
ES (1) ES2928395T3 (pl)
IL (1) IL298541B1 (pl)
MX (1) MX2022014900A (pl)
NZ (1) NZ794833A (pl)
PL (1) PL3902541T3 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
WO2020245133A1 (en) 2019-06-03 2020-12-10 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103189A1 (en) * 2006-10-19 2008-05-01 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted indoles
PL3844147T3 (pl) * 2019-11-07 2022-07-18 Small Pharma Ltd Związki chemiczne

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
WO2020245133A1 (en) 2019-06-03 2020-12-10 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADAM L HALBERSTADT; ET AL，BEHAVIORAL EFFECTS OF [ALPHA],[ALPHA],[BETA],[BETA]-TETRADEUTERO-5-MEO-DMT IN RATS: 以下備考，PSYCHOPHARMACOLOGY，ドイツ，SPRINGER，2012年01月06日，VOL:221, NR:4，PAGE(S):709 - 718，http://dx.doi.org/10.1007/s00213-011-2616-6，COMPARISON WITH 5-MEO-DMT ADMINISTERED IN COMBINATION WITH A MONOAMINE OXIDASE INHIBITOR
PHILIP E MORRIS JR; ET AL，INDOLEALKYLAMINE METABOLISM: SYNTHESIS OF DEUTERATED INDOLEALKYLAMINES AS METABOLIC PROBES，JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS，英国，JOHN WILEY & SONS LTD，1993年06月，VOL:33, NR:6，PAGE(S):455 - 465，http://dx.doi.org/10.1002/jlcr.2580330603
RUCHANOK TEARAVARICH; ET AL，MICROWAVE-ACCELERATED PREPARATION AND ANALYTICAL CHARACTERIZATION OF 5-ETHOXY-N,N-DIALKYL- 以下備考，DRUG TESTING AND ANALYSIS，英国，2011年09月，VOL:3, NR:9，PAGE(S):597 - 608，http://dx.doi.org/10.1002/dta.223，[[ALPHA],[ALPHA],[BETA],[BETA]-H4]- AND [[ALPHA],[ALPHA],[BETA],[BETA]-D4]-TRYPTAMINES

Also Published As

Publication number Publication date
AU2021204158A1 (en) 2023-01-05
NZ794833A (en) 2023-03-31
JP2023520256A (ja) 2023-05-16
CA3179161C (en) 2023-10-31
PL3902541T3 (pl) 2022-11-14
CA3179161A1 (en) 2021-06-17
CN116056763A (zh) 2023-05-02
CN116056763B (zh) 2024-03-05
KR102589605B1 (ko) 2023-10-13
ES2928395T3 (es) 2022-11-17
KR20230007547A (ko) 2023-01-12
IL298541B1 (en) 2024-04-01
MX2022014900A (es) 2023-03-27
IL298541A (en) 2023-01-01
AU2021204158B2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
EP3902541B1 (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11471417B2 (en) Deuterated N,N-dimethyltryptamine compounds
AU2020381103B2 (en) Compounds
JP2022535093A (ja) 重水素化された又は部分的に重水素化されたｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物
US11773062B2 (en) Deuterated compounds
TW202237565A (zh) 氘化化合物
JP7288154B2 (ja) 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物
JP2021525789A (ja) 縮合三環性γ−アミノ酸誘導体の組成物及びその調製
GB2605144A (en) Deuterated compounds
JP2023527575A (ja) 治療用固形製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230202

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230525

R150 Certificate of patent or registration of utility model

Ref document number: 7288154

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350